Loading
A chemotherapy-free combination of rituximab and lenalidomide worked as well as rituximab with chemotherapy for untreated follicular lymphoma, though not better, with different side effects.
Open-label phase 3 superiority trial: 1,030 patients with previously untreated follicular lymphoma were randomised to rituximab plus lenalidomide (513) or rituximab plus chemotherapy (517), each followed by rituximab maintenance.
Confirmed or unconfirmed complete response at 120 weeks was 48 percent against 53 percent (p 0.13) and interim three-year progression-free survival 77 against 78 percent. Grade 3 or 4 neutropenia (32 against 50 percent) and febrile neutropenia (2 against 7 percent) were more common with chemotherapy; grade 3 or 4 cutaneous reactions (7 against 1 percent) were more common with lenalidomide.
Rituximab-lenalidomide is an accepted chemotherapy-free first-line alternative for follicular lymphoma, chosen on toxicity profile and patient preference rather than efficacy.
Shares Lenalidomide, Rituximab, Follicular lymphoma.
Shares Rituximab, Follicular lymphoma, New England Journal of Medicine.
Shares Rituximab, Follicular lymphoma.
Shares Lenalidomide, Rituximab, Follicular lymphoma.
Shares Lenalidomide, Rituximab, Follicular lymphoma.
Shares Lenalidomide, Rituximab, Follicular lymphoma.
Shares Lenalidomide, Rituximab, Follicular lymphoma.
Shares Lenalidomide, Rituximab, Follicular lymphoma.